Evidence map›Paper›PMID 33625572›Full record

ArticleAnnals of hematology2021

High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma.

Ryszard Swoboda, Sebastian Giebel, Wanda Knopińska-Posłuszny, Ewa Chmielowska, Joanna Drozd-Sokołowska, Ewa Paszkiewicz-Kozik, Waldemar Kulikowski, Michał Taszner, Włodzimierz Mendrek, Jacek Najda and 10 more

Erratum issuedOpen access · hybridAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 10 institutions in 1 country.

Ryszard SwobodaDepartment of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Sebastian GiebelDepartment of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Wanda Knopińska-PosłusznyDepartment of Hematology and Bone Marrow Transplantation, Pomeranian Hospitals, Gdynia, Poland.
Ewa ChmielowskaOncologic Hospital, Tomaszów Mazowiecki, Poland.
Joanna Drozd-SokołowskaDepartment of Hematology, Oncology and Internal Diseases, Medical University of Warsaw, Warsaw, Poland.
Ewa Paszkiewicz-KozikDepartment of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw branch, Warsaw, Poland.
Waldemar KulikowskiDepartment of Hematology, Independent Public Health Care Ministry of the Interior of Warmia and Mazury Oncology Center, Olsztyn, Poland.
Michał TasznerDepartment of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland.
Włodzimierz MendrekDepartment of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Jacek NajdaDepartment of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Tomasz CzerwDepartment of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice branch, Gliwice, Poland.
Magdalena Olszewska-SzopaDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland.
Anna CzyżDepartment of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland.
Agnieszka GizaDepartment of Hematology, Jagiellonian University, Krakow, Poland.
Wojciech SpychałowiczInternal Medicine and Oncology Clinic, Silesian Medical University, Katowice, Poland.
Edyta SuboczDepartment of Hematology, Military Institute of Medicine, Warsaw, Poland.
Paweł SzwedykDepartment of Hematology, Ludwik Rydygier Hospital, Krakow, Poland.
Aleksandra KrzywonDepartment of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Agata WilkDepartment of Biostatistics and Bioinformatics, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Jan Maciej ZauchaDepartment of Hematology and Transplantology, Medical University of Gdańsk, Gdańsk, Poland. jzaucha@gumed.edu.pl.ORCID http://orcid.org/0000-0002-0986-8936
The Maria Sklodowska-Curie National Research Institute of Oncology · PLGdańsk Medical University · PLWroclaw Medical University · PLJagiellonian University · PLMedical University of Silesia · PLMedical University of Warsaw · PLPomeranian Medical University · PLUniversity of Bydgoszcz · PLUniversity of Warmia and Mazury in Olsztyn · PLWojskowy Instytut Medycyny Lotniczej · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal salvage therapy in relapsed/refractory Hodgkin lymphoma (R/R HL) has not been defined so far. The goal of this multicenter retrospective study was to evaluate efficacy and safety of BGD (bendamustine, gemcitabine, dexamethasone) as a second or subsequent line of therapy in classical R/R HL. We have evaluated 92 consecutive R/R HL patients treated with BGD. Median age was 34.5 (19-82) years. Fifty-eight patients (63%) had received 2 or more lines of chemotherapy, 32 patients (34.8%) radiotherapy, and 21 patients (22.8%) an autologous hematopoietic stem cell transplantation (autoHCT). Forty-four patients (47.8%) were resistant to first line of chemotherapy. BGD therapy consisted of bendamustine 90 mg/m

Indexed as

Salvage TherapyAdultAgedAged, 80 and overAllograftsAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideCombined Modality TherapyDeoxycytidineDexamethasoneDrug EvaluationFemaleGemcitabineHematologic DiseasesHematopoietic Stem Cell TransplantationHodgkin DiseaseBendamustine HydrochlorideDeoxycytidineDexamethasoneGemcitabineChemotherapyHodgkin lymphomaSalvageTreatment

Identifiers

PMID33625572
PMCPMC8195914
OpenAlexW3130584872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.